Transfusion-related mortality: The ongoing risks of allogeneic blood transfusion and the available strategies for their prevention

Blood

Volumn 113, Issue 15, 2009, Pages 3406-3417

  Vamvakas, Eleftherios C ^a   Blajchman, Morris A ^b,c,d  

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b MCMASTER UNIVERSITY   (Canada)

^c CANADIAN BLOOD SERVICES   (Canada)

^d MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOGENEIC BLOOD TRANSFUSION; ANAPHYLAXIS; BLOOD TRANSFUSION; BLOOD TRANSFUSION REACTION; CAUSAL ATTRIBUTION; HUMAN; HYPERVOLEMIA; MORTALITY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SEPSIS; TRANSFUSION ASSOCIATED GRAFT VERSUS HOST DISEASE; TRANSFUSION RELATED ACUTE LUNG INJURY;

EID: 65349166375     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2008-10-167643     Document Type: Review

References (91)

1. FDA/CBER. Fatalities reported to FDA following blood collection and transfusion. Annual summary for fiscal year 2007. http://www.fda.gov/cber/blood/ fatal07.htm. Accessed November 21, 2008.
2. Andreu G, Morel P, Forester F, et al. Hemovigi- lance network in France: organization and analysis of immediate transfusion incident reports from 1994 to 1998. Transfusion. 2002;42:1356-1364.
3. Stainsby D, Jones H, Asher D, et al, on behalf of the SHOT Seeing Group. Serious hazards of transfusion: a decade of hemovigilance in the UK Trans Med Rev. 2006;20:237-282.
4. Serious hazards of transfusion (SHOT) Annual Reports. http://www.shot-uk.org. Accessed September 10, 2008.
5. Robillard P, Nawej KI, Jochem K. The Quebec
6. hemovigilance system: description and results from the first two years. Transfus Apher Sci. 2004;31:111-122.
7. Sazama K. Reports of 355 transfusion-associated deaths: 1976 through 1985. Transfusion. 1990;30:583-590.
8. Dodd RY. Germs, gels, and genomes: a personal recollection of 30 years in blood-safety testing. In:
9. Stramer SL, ed. Blood Safety in the New Millennium. Bethesda, MD: American Association of Blood Banks; 2001:99-121.
10. Alter HJ. Pathogen reduction: Aprecautionary- principle paradigm. Transfus Med Rev. 2008;22: 97-102.
11. Pealer LN, Marfin AA, Petersen LR, et al, for the West Nile Virus Transmission Investigation Team. Transmission of West Nile virus through blood transfusion in the United States in 2002. N Engl J Med. 2003;349:1236-1245.
12. Zou S, Fang CT, Schoenberger LB. Transfusion transmission of prion diseases. Transfus Med Rev. 2008;22:58-69.
13. Rezza G, Nicoletti L, Angelini R, et al, for the CHIKV Study Group. Infection with Chickungunya virus in Italy: an outbreak in a temperate region. Lancet. 2007;370:1840-1846.
14. Wilson K, Wilson M, Hebert PC, Graham I. The application of the precautionary principle to the blood system: the Canadian blood system's vCJD donor deferral policy. Transfus Med Rev. 2003;17: 89-94.
15. van de Watering LMG, Hermans J, Houbiers JGA, et al. Beneficial effect of leukocyte depletion of transfused blood on post-operative complications in patients undergoing cardiac surgery: a randomized clinical trial. Circulation. 1998;97: 562-568.
16. Bilgin YM, van de Watering LMG, Eijsman L, et al. Double-blind, randomized controlled trial on the effect of leukocyte-depleted erythrocyte transfusions in cardiac-valve surgery. Circulation. 2004;109:2755-2760.
17. Boshkov LK, FurnaryA, Morris C, Chien G, van Winkle D, Reik R. Pre-storage leukoreduction of red cells in elective cardiac surgery: results of a double-blind randomized controlled trial. Blood. 2004;104:112a.
18. Strong DM, AuBuchon J, Whitaker B, Kuehnert MJ. Biovigilance initiatives. ISBT Science Series. 2008;3:77-84.
19. Renaudier P, Vo Mai MP, Schlanger S, et al. The declining risk of ABO incompatibilities: twelve years of hemovigilance in France. Blood. 2007; 118 (suppl 1):851A.
20. Whitaker BI, Green J, King MR, Leibeg LL, Schlumpf KS, Schreiber GB. The 2007 Nationwide Blood Collection and Utilization Survey Report. Washington, DC: Department of Heath and Human Services; 2008.
21. Kleinman S, Chan P, Robillard P. Risks associated with transfusion of cellular blood components in Canada. Transfus Med Rev. 2003;17: 120-162.
22. Gubernot DM, Lucey CT, Lee KC, Conley GB, Holness LG, Wise RP. Babesia infection through blood transfusions: reports received by the US Food and Drug Administration, 1997-2007. Clin Infect Dis. 2009;48:25-30.
23. Kleinman S, Caulfield T, Chan P, et al. Toward an understanding of transfusion-related acute lung injury: statement of a consensus panel. Transfusion. 2004;44:1774-1789.
24. Webert MA, Blajchman MA. Transfusion-related acute lung injury. Curr Opin Hematol. 2005;12: 480-487.
25. Popovsky MA, Moore SB. Diagnostic and patho-genetic considerations in transfusion-related acute lung injury. Transfusion. 1985;25:573-577.
26. Eder AF, Herron R, Strupp A, et al. Transfusion- related acute lung injury surveillance (2003-2005) and the potential impact of the selective use of plasma from male donors in the American Red Cross. Transfusion. 2007;47:599-607.
27. Wallis JP, Lubenko A, Wells AW, Chapman CE. Single hospital experience of TRALI. Transfusion. 2003;43:1053-1059.
28. Densmore TL, Goodnough LT, Ali S, Dynis M, Chaplin H. Prevalence of HLA sensitization in female apheresis donors. Transfusion. 1999;39: 103-106.
29. Palfi M, Berg S, Berlin G. Arandomized controlled trial of transfusion-related acute lung injury: is plasma from multiparous blood donors dangerous? Transfusion. 2001;41:317-322.
30. Strong DM, Shoos Lipton K. Transfusion-related acute lung injury. AABB Association Bulletin #06-07 (November 3, 2006). http://www.aabb.org/Content/ Members-Area/Association-Bulletins/. Accessed November 14, 2008.
31. Silliman CC, Ambruso DR, Boshkov LK. Transfusion-related acute lung injury. Blood. 2005;105: 2266-2273.
32. Honig CL, Bove JR. Transfusion-associated fatalities: review of Bureau of Biologics reports, 1976-78. Transfusion. 1980;20:653-661.
33. Linden JV, Wagner K, Voytovich AE, Sheehan J. Transfusion errors in New York State. Transfusion. 2000;40:1207-1213.
34. 69 Federal register 9120, February 26, 2004. See 21 CFR 606. 121 (c) (13).
35. Wenz B, Burns ER. Improvement in transfusion safety using a new blood-unit and patient identification system as part of safe transfusion practice. Transfusion. 1991;31:401-403.
36. Turner CL, Casbard AC, Murphy MF. Barcode technology: its role in increasing the safety of blood transfusion. Transfusion. 2003;43:1200- 1209.
37. Dzik WH, Murphy MF, Andrews G, et al. An international study of the performance of sample collection from patients. Vox Sang. 2003;85:40-47.
38. Castro O, Sandler SG, Houston-Yu P, Rana S. Predicting the effect of transfusing only pheno- type-matched RBCs to patients with sickle-cell disease: theoretical and practical implications. Transfusion. 2002;42:684-690.
39. Schonewille H, van de Watering LM, Brand A. Additional red-blood-cell alloantibodies after blood transfusions in a non-hematologic alloim- munized patient cohort: is it time to take precautionary measures? Transfusion. 2006;46:630-635.
40. Hillyer CD, Shaz BH, Winkler AM, Reid M. Integrating molecular technologies for red-blood-cell typing and compatibility testing into blood centers and transfusion services. Transfus Med Rev. 2008;22:117-132.
41. Scott MD, Bradley AJ, Murad KL. Camouflaged blood cells: low-technology bioengineering for transfusion medicine? Transfus Med Rev. 2000; 14:53-63.
42. Williamson LM, Stainsby D, Jones H, et al. The impact of universal leukodepletion of the blood supply on hemovigilance reports of post-transfusion purpura and transfusion-associated graft- versus-host disease. Transfusion. 2007;47:1455-1467.
43. Yasuura K, Okamoto H, MatsuuraA. Transfusion- associated graft-versus-host disease with transfusion practice in cardiac surgery. J Cardiovasc Surg. 2000;41:377-380.
44. Rososhansky S, Badonnel MC, Hiestand LL, Popovsky MA, Szymanski IO. Transfusion-associated graft-versus-host disease in an immuno-competent patient following cardiac surgery. Vox Sang. 1999;76:59-63.
45. Luban NL, DePalma L. Transfusion-associated graft-versus-host disease in the neonate: expanding the spectrum of disease. Transfusion. 1996;36:101-103.
46. Anderson KC. Current trends: evolving concepts in transfusion medicine. Leukodepleted cellular blood components for prevention of transfusion- associated graft-versus-host disease. Transfus Sci. 1995;16:265-268.
47. Jensen LS, Kissmeyer-Nielsen P, Wolff B, Quist N. Randomized comparison of leukocyte-depleted versus buffy-coat-poor blood transfusion and complications after colorectal surgery. Lancet. 1996;348:841-845.
48. Nielsen HJ, Hammer JH, Kraup AL, et al. Pre- storage leukocyte filtration may reduce leukocyte- derived bioactive substance accumulation in patients operated for burn trauma. Burns. 1999;25: 162-170.
49. Titlestad IL, Ebbesen LS, Ainsworth AP, Lillevang ST, Quist N, Georgsen J. Leukocyte-depletion of blood components does not significantly reduce the risk of infectious complications: results of a double-blind, randomized study. Int J Colorectal Dis.2001;16:147-153.
50. Dzik WH, Anderson JK, O'Neill EM, Assman SF, Kalish LA, Stowell CP. A prospective, randomized clinical trial of universal WBC reduction. Transfusion. 2002;42:1114-1122.
51. Wallis JP, Chapman CE, Orr KE, Clark SC, Forty JR. Effect of WBC reduction of transfused RBCs on postoperative infection rates in cardiac surgery. Transfusion. 2002;42:1127-1134.
52. van Hilten JA, van de Watering LMG, van Bockel JH, et al. Effects of transfusion with red cells filtered to remove leukocytes: randomized controlled trial in patients undergoing major surgery. BMJ. 2004;328:1281-1284.
53. Bracey AW, Radovancevick R, Nussimeier NA, LaRocco M, Vaughn WK, Cooper JR. Leukocyte- reduced blood in open-heart surgery patients: effects on outcome. Transfusion. 2002;42(suppl): 5S.
54. Nathens AB, Nester TA, Rubenfeld GD, Nirula R, Gernsheimer TB. The effects of leukoreduced blood transfusion on infection risk following injury: a randomized controlled trial. Shock. 2006;26: 342-347.
55. Vamvakas EC. White-blood-cell-containing allo- geneic blood transfusion and postoperative infection or mortality: an updated meta-analysis. Vox Sang. 2007;92:224-232.
56. Bilgin Y, Brand A. Transfusion-related immuno- modulation: a second hit in an inflammatory cascade? Vox Sang. 2008;95:261-271.
57. Vamvakas E, Blajchman MA. Transfusion-related immunomodulation (TRIM): an update. Blood Rev. 2007;21:327-348.
58. Koch GC, Li L, Sessler DI, et al. Duration of red- cell storage and complications after cardiac surgery. N Engl J Med. 2008;358:1229-1231.
59. Silliman CC, Clay KL, Thurman GW, Johnson CA, Ambruso DR. Partial characterization of lipids that develop during the routine storage of blood and prime the neutrophil NADPH oxidase. J Lab Clin Med. 1994;124:684-694.
60. Zallen G, Moore EE, Ciesla DJ, Brown M, Biffl WL, Silliman CC. Stored red blood cells selectively activate human neutrophils to release IL-8 and secretory PLA2. Shock. 2000;13:29-33.
61. Zimm AB, Hess JR. Current issues related to the transfusion of stored red blood cells. Vox Sang. 2009;96:93-103.
62. Hebert PC, Wells G, Blajchman MA, et al. Amulti- center randomized controlled trial of transfusion requirements in critical care. N Engl J Med. 1999; 340:409-417.
63. Dodd RY, Notari EP 4th, Stramer SL. Current prevalence and incidence of infectious disease markers and estimated window-period risk in the American Red Cross blood donor population. Transfusion. 2002;42:975-979.
64. Vamvakas E. Uses and sources of data on long- term survival after blood transfusion. Transfus Med Rev. 2003;17:194-208.
65. PereiraA. Cost-effectiveness of transfusing virus- inactivated plasma instead of standard plasma. Transfusion. 1999;39:479-487.
66. Pereira A, Sanz C. A model of the health and economic impact of post-transfusion hepatitis C: application to cost-effectiveness analysis of further expansion of HCV screening protocols. Transfusion. 2000;40:1182-1191.
67. Pereira A. Health and economic impact of post- transfusion hepatitis B and cost effectiveness analysis of expanded HBV testing protocols of blood donors: a study focused on the European Union. Transfusion. 2003;43:192-201.
68. Macedo de Oliveira A, Beecham BD, Montgomery SP, et al. West Nile virus blood transfusion- related infection despite nucleic acid testing. Transfusion. 2004;44:1695-1699.
69. Tambyah PA, Koav ES, Poon ML, Lin RV, Ong BK. Dengue hemorrhagic fever transmitted by blood transfusion. N Engl J Med. 2008;359:1526-1527.
70. National CJD Surveillance Unit. www.cjd.ed.ac.uk/figures.htm. Accessed June 2,2008.
71. Ghani AC, Donnelly CA, Fergusson NM, Anderson RM. Updated projections of future vCJD deaths in the UK. BMC Infect Dis. 2003;3:4
72. Hilton DA, Ghanmi AC, Conyers L, et al. Prevalence of lymphorecticular prion protein accumulation in UK tissue samples. J Pathol. 2004;203: 733-739.
73. Saa P, Castilla J, Soto C. Pre-symptomatic detection of prions in blood. Science. 2006;313:92-94.
74. Ness P, Braine N, King K, et al. Single-donor platelets reduce the risk of septic platelet transfusion reactions. Transfusion. 2001;41:857-861.
75. Perez P, Sahmi LR, Follea G, et al, for the BACTHEM Group, French Hemovigilance Network. Determinants of transfusion-associated bacterial contamination: results of the French BACTHEM case-control study. Transfusion. 2001;41:862-872.
76. Kuehnert MJ, Roth VR, Haley NR, et al. Transfusion-transmitted bacterial infection in the United States, 1998 through 2000. Transfusion. 2001;41: 1493-1499.
77. McDonald CP, Blajchman MA. Bacterial contamination in blood and blood components. In: Barbara JSJ, Regan FAM, Contreras MC, eds. Transfusion Microbiology. Cambridge, UK: Cambridge University Press; 2008:87-115.
78. Brecher ME, Holland PV, PinedaAA, Tegtmeier GE, Yomtovian R. Growth of bacteria in inoculated platelets: implications for bacterial detection and the extension of platelet storage. Transfusion. 2000;40:1308-1312.
79. Wagner SJ, Maroff G, Katz AJ, Friedman LI. Comparison of bacterial growth in single and pooled platelet concentrates after deliberate inoculation and storage. Transfusion. 1995;35: 298-303.
80. Murphy WG, Foley M, Doherty C, et al. Screening platelet concentrates for bacterial contamination: low numbers of bacteria and slow growth in contaminated units mandate an alternate approach to product safety. Vox Sang. 2008;95:13-19.
81. Benjamin RJ, Wagner SJ. The residual risk of sepsis: modeling the effect of concentration on bacterial detection in two-bottle culture systems and an estimation of false-negative culture rates. Transfusion. 2007;47:1381-1389.
82. Eder AF, Kennedy JM, Dy BA, et al. Bacterial screening of apheresis platelets and the residual risk of septic transfusion reactions: the American Red Cross experience (2004-2006). Transfusion. 2007;47:1134-1142.
83. Vamvakas EC, Blajchman MA. Universal WBC reduction: the case for and against. Transfusion. 2001;41:691-712.
84. Murphy W. Managing threats rather than risks in blood transfusion: robust design for a complex system. Transfusion. 2006;46:2011-2013.
85. Peterman TA, Lui K-J, Lawrence DN, Allen JR. Estimating the risks of transfusion-associated acquired immune deficiency syndrome and human immunodeficiency virus infection. Transfusion. 1987;27:371-374.
86. Seef LB, Hollinger FB, Alter HJ, et al. Long-term mortality and morbidity of transfusion-associated non-A, non-B, and type C hepatitis: a National Heart, Lung and Blood Institute Collaborative Study. Hepatology. 2001;33:455-463.
87. Allain JP, Bianco C, Blajchman MA, et al. Protecting the blood supply from emerging pathogens: the role of pathogen inactivation. Transfus Med Rev. 2005;19:110-126.
88. McCullough J. Pathogen inactivation: a new para-digm for blood safety. Transfusion. 2007;47:2180-2184.
89. Klein HG, Anderson D, Bernardi MJ, et al. Pathogen inactivation: making decisions about new technologies. Report of a consensus conference. Transfusion. 2007;47:238-247.
90. Custer B, Hoch JS. Cost-effectiveness analysis: what it really means for transfusion medicine decision making. Transfus Med Rev. 2009;23:1-12.
91. Muller U, Exadactylos A, Roeder C, Pisan M, Eggli S, Juni P. Effect of flow chart on use of blood transfusions in primary total-hip and knee replacement: prospective before-and-after study. Br Med J. 2004;328:934-938.